Table 2.
Evaluation of the markers using the validation set with 16 non-lepidic AD and 11 PDSCC patients
| AD markers | (Marker status) | (+) | (−) | Sensitivity | Specificity | PPV | NPV | Accuracy | ||
| (subtype) | AD | SCC | AD | SCC | (95 % CI†) | (95 % CI) | (95 % CI) | (95 % CI) | (95 % CI) | |
| ST6GALNAC1* | 15 | 0 | 1 | 11 | 0.938 (0.698–0.998) |
1.000 (0.715–1.000) |
1.000 (0.782–1.000) |
0.917 (0.615–0.998) |
0.963 (0.810–0.999) |
|
| TTF-1 | 10 | 0 | 6 | 11 | 0.625 (0.354–0.848) |
1.000 (0.715–1.000) |
1.000 (0.692–1.000) |
0.647 (0.383–0.858) |
0.778 (0.577–0.914) |
|
| napsin A | 12 | 0 | 4 | 11 | 0.750 (0.476–0.927) |
1.000 (0.715–1.000) |
1.000 (0.735–1.000) |
0.733 (0.449–0.922) |
0.852 (0.663–0.958) |
|
| SCC markers | (Marker status) | (+) | (−) | Sensitivity | Specificity | PPV | NPV | Accuracy | ||
| (subtype) | SCC | AD | SCC | AD | (95 % CI) | (95 % CI) | (95 % CI) | (95 % CI) | (95 % CI) | |
| SPATS2* | 7 | 0 | 4 | 16 | 0.636 (0.308–0.891) |
1.000 (0.794–1.000) |
1.000 (0.590–1.000) |
0.800 (0.563–0.943) |
0.852 (0.663–0.958) |
|
| CK5 | 7 | 0 | 4 | 16 | 0.636 (0.308–0.891) |
1.000 (0.794–1.000) |
1.000 (0.590–1.000) |
0.800 (0.563–0.943) |
0.852 (0.663–0.958) |
|
| DSG3 | 6 | 0 | 5 | 16 | 0.545 (0.234–0.833) |
1.000 (0.794–1.000) |
1.000 (0.541–1.000) |
0.762 (0.528–0.918) |
0.815 (0.619–0.937) |
|
| p40 | 7 | 0 | 4 | 16 | 0.636 (0.308–0.891) |
1.000 (0.794–1.000) |
1.000 (0.590–1.000) |
0.800 (0.563–0.943) |
0.852 (0.663–0.958) |
|
| CK6 | 5 | 9 | 6 | 7 | 0.455 (0.167–0.766) |
0.438 (0.198–0.701) |
0.357 (0.128–0.649) |
0.538 (0.251–0.808) |
0.444 (0.255–0.647) |
|
PPV Positive predictive value, NPV Negative predictive value, 95 % CI 95 % confidence interval
†: 95 % CIs of sensitivity, specificity, PPV, NPV and accuracy were estimated by the Clopper-Pearson method
* Novel biomarkers identified in the present study